Unused borrowing capacity $745M $736.7 $351.1 $693.3 LTM 4Q21 LTM 4Q22 LTM 4Q23 Capital Expenditures ($M) Free Cash Flow ($M) $102.7 $134.8 $119.7 LTM 4Q21 LTM 4Q22 LTM 4Q23 $634.0 $216.3 $573.6 LTM 4Q21 LTM 4Q22 LTM 4Q23 Expect liquidity to improve as supply chain environment improves and inventory levels come down 9 © 2023 ResMed | Q4 2023 Earnings Presentation – Aug. 3, 2023 Track record of strong financial returns for shareholders (Financial data as of June 30, 2023) Revenue ($B) Non-GAAP Operating Inco ...

ResMed, Inc. (NYSE:RMD) Q4 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications & IRO Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President & COO Lucile Blaise - President, Sleep & Respiratory Care Conference Call Participants Matthew Mishan - KeyBanc Capital Markets Margaret Kaczor - William Blair Anthony Petrone - Mizuho Group Shaymus Contorno - Oppenheimer Laura Sutcliffe - UBS Sean Laaman - Morgan Stanley Lyanne Harrison - Bank of Am ...

ResMed Inc. (NYSE:RMD) Q3 2023 Earnings Conference Call April 27, 2023 4:30 PM ET Company Participants Amy Wakeham - Vice President, Investor Relations Mick Farrell - Chief Executive Officer and Chairman Brett Sandercock - Chief Financial Officer Rob Douglas - President and Chief Operating Officer David Pendarvis - Global General Counsel, Chief Administrative Officer Conference Call Participants Lyanne Harrison - Bank of America Dan Hurren - MST Macquarie Gretel Janu - Credit Suisse Matt Taylor - Jefferies ...

Q3 FY2023 Earnings 3 © 2023 ResMed | Q3 2023 Earnings Presentation – Apr. 27, 2023 During the last 12 months, we changed over 156 million lives* with our digital health products and cloud-based software solutions Our mission is to change 250 million lives in 2025 We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD, and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice Founded 1989 Devices Masks & Oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

ResMed Inc. (NYSE:RMD) Q2 2023 Earnings Conference Call January 26, 2023 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO and Chairman Brett Sandercock - CFO Rob Douglas - President and COO Conference Call Participants Chris Cooper - Goldman Sachs Suraj Kalia - Oppenheimer Matthew Mishan - KeyBanc Capital Markets Steve Wheen - Jarden David Bailey - Macquarie Mike Matson - Needham & Company Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margaret Kaczor - W ...

Three Months Ended Six Months Ended GAAP income from operations Amortization of acquired intangibles—cost of sales (A) Amortization of acquired intangibles—operating expenses (A) Amortization of acquired intangibles—operating expenses, net of tax (A) GAAP diluted shares outstanding (A) ResMed adjusts for the impact of the amortization of acquired intangibles, acquisition-related expenses, and the reserve for disputed tax positions from their evaluation of ongoing operations and believes that investors benef ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 F ...

ResMed Inc. (NYSE:RMD) Q1 2023 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO & Director Brett Sandercock - CFO Rob Douglas - President, COO and Interim President, Sleep & Respiratory Care David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants Steve Wheen - Jarden Matt Mishan - KeyBanc Gretel Janu - Credit Suisse Saul Hadassin - Barrenjoey Capital Dan Hurren - MST Mar ...

Q1 FY2023 Earnings October 27, 2022 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financi ...